A topological optimization method and system for personalized drug controlled release system

The drug controlled release system is designed through topological optimization methods, and the problems of limited design freedom and neglected influence of drug concentration distribution in the existing technology are solved, and the accurate release and uniform concentration distribution of drugs at the targeted site are achieved, which improves the therapeutic effect.

CN114117866BActive Publication Date: 2024-11-22XIAN UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111470442.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-12-03
Publication Date
2024-11-22
Estimated Expiration
2041-12-03

AI Technical Summary

Technical Problem

The existing drug controlled release system has limited freedom in designing, making it difficult to achieve accurate drug release at the targeted site, and the impact of drug concentration distribution in the cavity on the drug release rules is not fully considered, resulting in poor treatment effect.

Method used

Using topology optimization method, a personalized drug controlled release system structure is designed by creating topology optimization models, finite element analysis and iterative optimization to meet the target concentration distribution and volume constraints and realize the optimal topology structure of the drug controlled release system.

Benefits of technology

It improves the design freedom and therapeutic effect of the drug controlled release system, realizes the uniform concentration distribution and accurate release of the drug at the targeted site, and improves the accuracy and efficiency of drug treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114117866B_ABST
    Figure CN114117866B_ABST
Patent Text Reader

Abstract

The present invention provides a topology optimization method and system for a personalized drug controlled release system, which has a higher degree of design freedom, can realize a structural design of a drug controlled release system with controllable internal concentration in combination with a target, meet personalized drug release needs, and maximize drug treatment effects. It includes S1, creating a topology optimization model, the creation process includes establishing a design domain in combination with the medication environment of the drug controlled release system, distinguishing and controlling each target material property through a SIMP interpolation model based on the variable density method, and setting boundary conditions, objective functions, constraints and design variables in combination with target medication needs; S2, performing finite element analysis on the topology optimization model, and calculating and obtaining the sensitivity information of the objective function to the design variables; S3, based on the sensitivity information, repeatedly iteratively optimizing the topology optimization model until the optimization convergence condition is met; S4, performing projection function calculation on the design variables that meet the optimization convergence condition to obtain the optimal topology structure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of optimization control of drug release behavior, and in particular to a topology optimization method and system for a personalized drug controlled release system. Background Art

[0002] With the development of modern medical technology, "precision medicine" as a new medical model has attracted strong attention from researchers in the medical field. Compared with traditional medicine, precision medicine can provide patients with more accurate diagnosis and treatment according to the specific cause of the patient's disease, so as to achieve precise treatment effect. In order to achieve precise control of drug release during treatment, drug controlled release system (CDDS) came into being and quickly became a research hotspot in the medical field. Drug controlled release system refers to a drug delivery mode that uses carriers with different structures to carry drugs and control the quantitative release of drugs at the target site at the required rate. It has the advantages of reducing the number of dosing times, accurately controlling drug release and improving patient compliance. Therefore, designing a drug controlled release system that meets the individual differences of patients has become an urgent problem to be solved.

[0003] In the existing structural design of drug controlled release systems, researchers have studied drug controlled release systems from multiple aspects such as carrier materials, preparation processes, and design optimization of carrier structures. However, these works have not deviated from the limitations of the original structure, and the design freedom is not high. The improvement of the controlled release ability of the drug controlled release system is limited, and there is a large deviation between the obtained optimization curve and the target curve. At the same time, the research process mainly focuses on the cumulative amount of released drugs, and also ignores the influence of the drug concentration distribution inside the cavity on the drug release law. As a reliable and effective optimization method, topological optimization can provide designers with extremely creative and most effective solutions in the conceptual design stage. However, there are very few studies on the application of topological optimization to the structural optimization design of drug controlled release systems. Therefore, it is very necessary to apply topological optimization to the structural design of drug controlled release systems, design specific carrier structures according to the expected goals, and improve the therapeutic effect of drugs. Summary of the invention

[0004] In order to solve the problems existing in the prior art, the present invention provides a topological optimization method and system for a personalized drug controlled release system, which has a higher degree of design freedom and high design efficiency, and can realize the structural design of the drug controlled release system with controllable internal concentration in combination with the target, meet the needs of personalized drug release, and maximize the drug treatment effect.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] A method for topological optimization of a personalized drug controlled release system comprises the following steps:

[0007] S1, create a topology optimization model. The creation process includes establishing a design domain in combination with the medication environment of the drug controlled release system and discretizing it into a finite element mesh model. Based on the variable density method, the properties of each target material in the design domain are differentiated and controlled through the solid isotropic material interpolation model (SIMP). The boundary conditions, objective functions, constraints and design variables of the finite element mesh model are set in combination with the target medication requirements. The topology optimization model is established.

[0008] S2, using material transfer finite element simulation method to perform finite element analysis on the topology optimization model, and calculate the sensitivity information of the objective function to the design variables;

[0009] S3, based on the obtained sensitivity information, the topology optimization model is iteratively optimized using the moving asymptote method until the preset optimization convergence conditions are met;

[0010] S4, projection function calculation is performed on the design variables that meet the optimization convergence conditions to obtain the optimal topological structure of the drug controlled release system.

[0011] Preferably, in step S1, the design variable is set as the diffusion coefficient of the drug in different materials, and the initial value of the design variable is set to 0.5.

[0012] Preferably, the objective function in S1 is set to minimize the difference between the actual average concentration in the design domain and the preset target concentration.

[0013] The expression of the objective function is,

[0014] Minf(x)=|C s -C ave |,

[0015] Among them, Minf(x) is the objective function, C S is the preset target concentration, C ave is the actual average concentration in the design domain.

[0016] Preferably, the constraint condition in S1 is set as the flow channel volume constraint, and its expression is:

[0017] ∫ Ω xdv≤q v ∫ Ω dv,x min ≤x≤1

[0018] Where x is the position of the design variable, v is the volume of the design domain, and q v is the volume constraint factor, which is used to determine the proportion of the flow channel volume to the total design domain volume.

[0019] Preferably, the volume constraint factor q vThe value range is 0.1 to 0.5.

[0020] Preferably, after S1, the step further includes filtering the design variables;

[0021] The design variables and filter radius are taken as input parameters, and the design variables are filtered by inputting them into the preset filter expression.

[0022] Preferably, the expression for filtering the preset design variables is:

[0023]

[0024] Among them, R min is the filter radius, γ f is the filtered design variable, γ s are the original input design variables, Represents the gradient operator.

[0025] Preferably, the optimization convergence condition preset in S3 is:

[0026] Max|γ k -γ k-1 |≤10 -6 k∈[0,∞)

[0027] Among them, k is the number of iterations, γ k is the design variable obtained when the number of iterations is k, γ k-1 is the design variable obtained when the number of iterations is k-1.

[0028] Preferably, the expression of the projection function in S4 is:

[0029]

[0030] Among them, β is used to control the steepness of the projection; γ β is the projection threshold, which is equal to the design variable that meets the optimization convergence condition; γ p are the design variables obtained after projection.

[0031] A topology optimization system for a personalized drug controlled release system, comprising:

[0032] The topology optimization model building module is used to create a topology optimization model. The creation process includes establishing a design domain in combination with the medication environment of the drug controlled release system and discretizing it into a finite element mesh model. Based on the variable density method, the properties of each target material in the design domain are differentiated and controlled through the solid isotropic material interpolation model (SIMP). The boundary conditions, objective functions, constraints and design variables of the finite element mesh model are set in combination with the target medication requirements. The topology optimization model is established.

[0033] A sensitivity calculation module is used to calculate and obtain the sensitivity information of the objective function to the design variables using the material transfer finite element simulation method;

[0034] The optimization iteration module is used to iteratively optimize the topology optimization model based on the obtained sensitivity information using the moving asymptote method until the preset optimization convergence conditions are met;

[0035] The projection module is used to calculate the projection function of the design variables that meet the optimization convergence conditions and obtain the optimal topological structure of the drug controlled release system.

[0036] Compared with the prior art, the present invention has the following beneficial effects:

[0037] The present invention provides a topology optimization method for a personalized drug controlled-release system. A topology optimization model is created based on a variable density topology optimization method in combination with target actual medication needs, including a design domain, a numerical model, boundary conditions, an objective function, constraints and design variables. Secondly, the sensitivity information of the objective function to the design variables is calculated by a material transfer finite element simulation method to update the values ​​of each design variable in the design domain. The topology optimization problem is solved by a moving asymptote method, and it is iterated repeatedly until the convergence condition is met, so as to finally obtain the optimal topology structure of the drug controlled-release system. The structural design of the personalized drug controlled-release system is realized, and the system has more flexible design freedom, further improves the therapeutic effect of the drug, provides theoretical support for the structural optimization design of the drug controlled-release system, and has practical value and guiding significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 It is a schematic diagram of the process of the topology optimization method of the present invention;

[0039] Figure 2 Schematic diagram of the initial model and boundary conditions of the reservoir-type drug controlled release system in an embodiment of the present invention;

[0040] Figure 3 is a schematic diagram of the topological optimization structure of the reservoir-type drug controlled release system in an embodiment of the present invention;

[0041] Figure 4 a is a non-optimized concentration distribution cloud diagram in an embodiment of the present invention;

[0042] Figure 4 b is the optimized concentration distribution cloud diagram in the embodiment of the present invention. DETAILED DESCRIPTION

[0043] The present invention is further described in detail below in conjunction with specific embodiments, which are intended to explain the present invention rather than to limit it.

[0044] like Figure 1As shown, the present invention provides a topology optimization method for a personalized drug controlled release system, comprising the following steps:

[0045] S1, create a topology optimization model. The creation process includes establishing a design domain in combination with the medication environment of the drug controlled release system and discretizing it into a finite element mesh model. Based on the variable density method, the properties of each target material in the design domain are differentiated and controlled through the solid isotropic material interpolation model (SIMP). The boundary conditions, objective functions, constraints and design variables of the finite element mesh model are set in combination with the target medication requirements. The topology optimization model is established.

[0046] S2, using material transfer finite element simulation method to perform finite element analysis on the topology optimization model, and calculate the sensitivity information of the objective function to the design variables;

[0047] S3, based on the obtained sensitivity information, the topology optimization model is iteratively optimized using the moving asymptote method until the preset optimization convergence conditions are met;

[0048] S4, projection function calculation is performed on the design variables that meet the optimization convergence conditions to obtain the optimal topological structure of the drug controlled release system.

[0049] The present invention provides a topology optimization method for a personalized drug controlled-release system. A topology optimization model is created based on a variable density topology optimization method in combination with target actual medication needs, including a design domain, a numerical model, boundary conditions, an objective function, constraints and design variables. Secondly, the sensitivity information of the objective function to the design variables is calculated by a material transfer finite element simulation method to update the values ​​of each design variable in the design domain. The topology optimization problem is solved by a moving asymptote method, and it is iterated repeatedly until the convergence condition is met, so as to finally obtain the optimal topology structure of the drug controlled-release system. The structural design of the personalized drug controlled-release system is realized, and the system has a more flexible design degree of freedom, which further improves the therapeutic effect of the drug.

[0050] The entire process of the topology optimization method for the personalized drug controlled release system of the present invention can be calculated in COMSOL Multiphysics software.

[0051] Preferably, in step S1, the design variable is set as the diffusion coefficient of the drug in different materials, and the initial value of the design variable is set to 0.5.

[0052] Preferably, the objective function in step S1 is set to minimize the difference between the actual average concentration of the design domain and the preset target concentration, and its expression is:

[0053] Minf(x)=|C s -C ave |

[0054] Among them, Minf(x) is the objective function, C S is the preset target concentration, C ave is the actual average concentration in the design domain. S value to achieve personalized customization of drug controlled release system.

[0055] Preferably, the constraint condition in step S1 is set as the flow channel volume constraint, and its expression is:

[0056] ∫ Ω xdv≤q v ∫ Ω dv,x min ≤x≤1

[0057] Where x is the position of the design variable, v is the volume of the design domain, and in this embodiment x min =0.001,q v is the volume constraint factor, which is used to determine the proportion of the flow channel volume to the total design domain volume.

[0058] Among them, the volume constraint factor q v The value range is 0.1 to 0.5.

[0059] Among them, the material properties of each drug refer to the different diffusion coefficients of the drug in the polymer matrix and the flow channel. The solid isotropic material interpolation model (SIMP) was established using the difference in diffusion coefficients. The expression is:

[0060]

[0061] Among them, D(x i ) is the diffusion coefficient of unit i, γ i is the design variable density value corresponding to unit i, ranging from 0 to 1, D min is the diffusion coefficient of the solid polymer material, D max is the diffusion coefficient of the flow channel area, when γ i = 0, the diffusion coefficient corresponding to this unit is the diffusion coefficient of the drug in the polymer matrix. i =1, the diffusion coefficient corresponding to this unit is the diffusion coefficient of the drug in the flow channel, and p is the penalty coefficient, which is used to make the design variable tend to 0 or 1 as much as possible, and the value range is 3 to 5.

[0062] Preferably, the sensitivity information of the objective function to the design variables is calculated and obtained in step S2, specifically including:

[0063] The adjoint method is used to calculate the sensitivity of the objective function to the design variables. The governing equations in COMSOL Multiphysics can automatically solve the adjoint problem and provide sensitivity for the objective function and constraints. The sensitivity of the objective function to the design variables calculated by the adjoint method is

[0064] Preferably, after the step S1, the design variables are also filtered; the design variables are filtered by inputting the design variables and the filtering radius as input parameters into a preset design variable filtering expression, specifically by coupling a Helmholtz type partial differential equation, and differentially solving the design variables through the differential equation to obtain the filtered design variables. The filtering and updating of the design variables is to suppress numerical instability phenomena in the optimization calculation process, such as "chessboard phenomenon", gray areas, etc.

[0065] Furthermore, the expression for filtering the preset design variables is:

[0066]

[0067] Among them, R min is the filter radius, γ f is the filtered design variable, γ s are the original input design variables, Represents the gradient operator, which is used to differentiate the design variables.

[0068] Preferably, the optimization convergence condition preset in step S3 is:

[0069] Max|γ k -γ k-1 |≤10 -6 k∈[0,∞)

[0070] Among them, k is the number of iterations, γ k is the design variable obtained when the number of iterations is k, γ k-1 is the design variable obtained when the number of iterations is k-1.

[0071] Preferably, the expression of the projection function in step S4 is:

[0072]

[0073] Among them, β is used to control the steepness of the projection; γ β is the projection threshold, which is equal to the design variable that meets the optimization convergence condition; γ p are the design variables obtained after projection.

[0074] The present invention also provides a personalized drug controlled release system topology optimization system, comprising:

[0075] The topology optimization model building module is used to create a topology optimization model. The creation process includes establishing a design domain in combination with the medication environment of the drug controlled release system and discretizing it into a finite element mesh model. Based on the variable density method, the properties of each target material in the design domain are differentiated and controlled through the solid isotropic material interpolation model (SIMP). The boundary conditions, objective functions, constraints and design variables of the finite element mesh model are set in combination with the target medication requirements. The topology optimization model is established.

[0076] A sensitivity calculation module is used to calculate and obtain the sensitivity information of the objective function to the design variables using the material transfer finite element simulation method;

[0077] The optimization iteration module is used to iteratively optimize the topology optimization model based on the obtained sensitivity information using the moving asymptote method until the preset optimization convergence conditions are met;

[0078] The projection module is used to calculate the projection function of the design variables that meet the optimization convergence conditions and obtain the optimal topological structure of the drug controlled release system.

[0079] Example

[0080] The present invention is further described by taking a reservoir-type drug controlled-release system as an example.

[0081] The initial model and boundary conditions of the reservoir-type drug controlled release system are as follows: Figure 2 As shown in the figure, the design domain size is 10mm*10mm, the drug reservoir diameter is 3mm, and an appropriate amount of drug is loaded in the reservoir to simulate the physiological environment at 37°C. The initial condition is set to aspirin concentration of 0 mol·m at the diffusion boundary. -3 The drug reservoir boundary concentration is set to the maximum solubility of aspirin, 55.506 mol·m -3 The target concentration was set at 43.934 mol·m -3 , and set q v =0.1, p=5.

[0082] The diffusion coefficient of aspirin in different regions is taken as the design variable, where the diffusion coefficient of aspirin in the polymer matrix is ​​1e -10 m 2 ·s -1 , the diffusion coefficient of aspirin in the flow channel region is 1e -9 m 2 ·s -1 , and establish a SIMP material interpolation model, complete the optimization solution algorithm, filter and projection conditions in COMSOL Multiphysics, and start the calculation by discretizing the design domain of the reservoir-type drug controlled release system into a grid.

[0083] The schematic diagram of the topological structure of the reservoir-type drug controlled release system is as follows: Figure 3 As shown, the white area and black area in the figure represent the flow channel and polymer material, respectively.

[0084] The concentration distribution diagram of reservoir-type drug controlled release system is shown in Figure 4 As shown, Figure 4 a is the unoptimized concentration distribution cloud diagram; Figure 4 b is the concentration distribution cloud diagram of the optimized system.

[0085] Depend on Figure 4 It can be seen from Figures 4a and 4b that the topology optimization method and system provided by the present invention can achieve uniform distribution of concentration. The streamlines represent the diffusion direction of the drug and a certain concentration gradient is formed along this direction. In addition, the overall concentration value of the entire design domain is improved, and the average concentration of the design domain reaches the expected target concentration value, realizing the structural design of a personalized drug controlled release system, with more flexible design freedom, and further improving the therapeutic effect of the drug.

[0086] To achieve the above-mentioned purpose, the main technical means adopted in the present invention shall be described clearly, completely and accurately, and the essential content of the invention shall be explained. The degree of disclosure shall be based on the understanding and implementation of ordinary technicians in the relevant technical field.

Claims

1. A topology optimization method for a personalized drug controlled release system, characterized in that: The following steps are included: S1, create a topology optimization model. The creation process includes establishing a design domain in combination with the medication environment of the drug controlled release system and discretizing it into a finite element mesh model. Based on the variable density method, the properties of each target material in the design domain are differentiated and controlled through the solid isotropic material interpolation model SIMP. The boundary conditions, objective functions, constraints and design variables of the finite element mesh model are set in combination with the target medication requirements. The topology optimization model is established. S2, using material transfer finite element simulation method to perform finite element analysis on the topology optimization model, and calculate the sensitivity information of the objective function to the design variables; S3, based on the obtained sensitivity information, the topology optimization model is iteratively optimized using the moving asymptote method until the preset optimization convergence conditions are met; S4, projection function calculation is performed on the design variables that meet the optimization convergence conditions to obtain the optimal topological structure of the drug controlled release system.

2. A method for topological optimization of a personalized drug controlled release system according to claim 1, characterized in that: In the step S1, the design variable is set as the diffusion coefficient of the drug in different materials, and the initial value of the design variable is set to 0.

5.

3. The method for topological optimization of a personalized drug controlled release system according to claim 1, characterized in that: The objective function in S1 is set to minimize the difference between the actual average concentration in the design domain and the preset target concentration. The expression of the objective function is, Minf(x)=|C s -C ave |, Among them, Minf(x) is the objective function, C S is the preset target concentration, C ave is the actual average concentration in the design domain.

4. The method for topological optimization of a personalized drug controlled release system according to claim 1, characterized in that: The constraint condition in S1 is set as the flow channel volume constraint, and its expression is: ∫ Ω xdv≤q v ∫ Ω dv,x min ≤x≤1 Where x is the position of the design variable, v is the volume of the design domain, and q v is the volume constraint factor, which is used to determine the proportion of the flow channel volume to the total design domain volume.

5. The method for topological optimization of a personalized drug controlled release system according to claim 4, characterized in that: The volume constraint factor q v The value range is 0.1 to 0.

5.

6. The method for topological optimization of a personalized drug controlled release system according to claim 1, characterized in that: After S1, it also includes filtering the design variables; The design variables and filter radius are taken as input parameters, and the design variables are filtered by inputting them into the preset filter expression.

7. The method for topological optimization of a personalized drug controlled release system according to claim 6, characterized in that: The expression for the preset design variable filtering is: Among them, R min is the filter radius, γ f is the filtered design variable, γ s are the original input design variables, Represents the gradient operator.

8. The method for topological optimization of a personalized drug controlled release system according to claim 1, characterized in that: The optimization convergence condition preset in S3 is: Max|c k -c k-1 |≤10 -6 k∈[0,∞) Among them, k is the number of iterations, γ k is the design variable obtained when the number of iterations is k, γ k-1 is the design variable obtained when the number of iterations is k-1.

9. The method for topological optimization of a personalized drug controlled release system according to claim 7, characterized in that: The expression of the projection function in S4 is: Among them, β is used to control the steepness of the projection; γ β is the projection threshold, which is equal to the design variable that meets the optimization convergence condition; γ p are the design variables obtained after projection.

10. A personalized drug controlled release system topology optimization system, characterized in that: A topology optimization method according to any one of claims 1 to 9, comprising: The topology optimization model building module is used to create a topology optimization model. The creation process includes establishing a design domain in combination with the medication environment of the drug controlled release system and discretizing it into a finite element mesh model. Based on the variable density method, the properties of each target material in the design domain are differentiated and controlled through the solid isotropic material interpolation model SIMP. The boundary conditions, objective functions, constraints and design variables of the finite element mesh model are set in combination with the target medication requirements. The topology optimization model is established. A sensitivity calculation module is used to calculate and obtain the sensitivity information of the objective function to the design variables using the material transfer finite element simulation method; The optimization iteration module is used to iteratively optimize the topology optimization model based on the obtained sensitivity information using the moving asymptote method until the preset optimization convergence conditions are met; The projection module is used to calculate the projection function of the design variables that meet the optimization convergence conditions and obtain the optimal topological structure of the drug controlled release system.